Docbot

What Docbot does

Dova Health Intelligence (formerly Satisfai Health, operating under the Docbot/Docbot.ai web identity) is a Vancouver-based AI health technology company building computer vision tools for gastrointestinal disease assessment. The company's core products are three deep-learning platforms: DovaVision UC, which performs frame-level Mayo Endoscopic Score (MES) and UCEIS scoring from colonoscopy videos for ulcerative colitis; DovaVision BE, a real-time Barrett's Esophagus surveillance and early esophageal adenocarcinoma detection system that received FDA Breakthrough Device Designation in December 2023; and DovaSound, an AI-powered intestinal ultrasound analysis platform for IBD monitoring in development. The proprietary stack is built on convolutional neural networks and self-supervised vision transformers trained on 108 million expertly annotated labels, delivering explainable three-layer (video, frame, pixel) outputs with embedded quality assurance and approximately 15-minute procedure turnaround.

The company monetizes through enterprise SaaS subscriptions on quote-based multi-year contracts, sold primarily to pharmaceutical companies running IBD clinical trials, contract research organizations, and academic medical centers. Distribution combines direct enterprise API integration with channel partnerships — most notably the Alimentiv Notō platform partnership (announced May 2025) and the Mayo Clinic collaboration (October 2025) for regulatory co-development. DovaVision UC is commercially available for research and clinical trial use, while DovaVision BE and DovaSound remain in development as medical devices. Target customers span pharma/biotech sponsors seeking standardized endoscopic endpoints, healthcare providers seeking AI-augmented GI assessment, and academic research networks contributing to model validation and co-development. The company's competitive position rests on a globally validated Scientific Advisory Board of 11 KOLs, patented Barrett's technology, FDA Breakthrough Designation, and the TITRATE randomized controlled trial demonstrating differential clinical outcomes with AI versus human endoscopic scoring.

The business operates from Vancouver, Canada with approximately 20-30 employees spanning clinical, engineering, regulatory, and commercial functions. Leadership includes Dr. Michael Byrne (Founder/Chairman/CMO, a Clinical Professor at UBC and practicing gastroenterologist with 150+ peer-reviewed papers), Solveig Johannessen (CEO, formerly of Deloitte Digital), Joseph Cianflone (CFO, joined May 2025), and Murray Flanigan (Co-Founder). The company is privately held with no disclosed institutional investors in the Dova era. Strategic priorities are FDA clearance for DovaVision UC MES, expansion of DovaSound into clinical practice, and broader commercialization of the platform through channel partners and direct enterprise sales to pharmaceutical trial sponsors.

Name

Docbot

Legal name

Dova Health Intelligence Inc.

Website

https://docbot.ai

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Dova Health Intelligence (formerly Satisfai Health) is a Vancouver-based AI health technology company building deep-learning computer vision tools that analyze gastrointestinal endoscopic and ultrasound imaging for pharmaceutical clinical trials, academic medical centers, and gastroenterology providers, with three products spanning ulcerative colitis, Barrett's Esophagus, and IBD intestinal ultrasound.

Ownership category

akta.pro rank

Product category

AI Medical Imaging Software

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software (HLACANAD)

akta.pro secondary industries

SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG), Medical Imaging AI (HDAAAEAH), Inflammatory Bowel Disease (IBD) Care (HLAKAEAD), General Gastroenterology (HLAKAEAA)

Keywords

• AI medical imaging
• Gastrointestinal diagnostics
• Endoscopy analysis software
• Clinical trial analytics
• Computer vision healthcare

Headquarters

HQ city

Irvine

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. DovaVision UC SaaS Platform: AI-powered software-as-a-service solution for analyzing colonoscopy videos in clinical trials. Currently available for research and clinical trials. Medical device in development. Revenue generated through SaaS subscriptions integrated via API or through partnership platforms like Alimentiv's Notō.
2. DovaVision BE (Development): AI-powered Barrett's Esophagus surveillance platform in development. FDA Breakthrough Device Designation received December 2023. Future revenue stream for clinical practice applications.
3. DovaSound (Development): AI-powered intestinal ultrasound imaging analysis for IBD assessment in development. Future revenue through research partnerships and clinical deployment.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Docbot (operating at docbot.ai as Dova Health Intelligence) develops AI-powered image analysis software for gastrointestinal care. Its products analyze colonoscopy videos for ulcerative colitis severity scoring, detect Barrett's Esophagus during live endoscopy, and process intestinal ultrasound images for IBD assessment. The platform is delivered as secure, API-integrated software for pharmaceutical clinical trials and research use.

Product overview

Dova Health Intelligence (formerly Satisfai Health) is a precision health technology company offering a portfolio of three AI-powered products for gastrointestinal care and research. DovaVision UC provides AI-powered colonoscopy video analysis for ulcerative colitis disease severity scoring; DovaVision BE offers real-time Barrett's Esophagus surveillance and early cancer detection; and DovaSound delivers AI-enhanced intestinal ultrasound analysis for IBD monitoring. The products share a common AI infrastructure platform and are designed to integrate into clinical and research workflows via secure APIs, supporting both pharmaceutical clinical trials and clinical practice.

Differentiator

Problem solved

Functional benefit

Brands

• DovaVision: AI-powered endoscopy analysis platform for gastrointestinal disease assessment, including DovaVision UC for Ulcerative Colitis and DovaVision BE for Barrett's Esophagus.
• DovaSound

Products and services

• DovaVision UC AI-powered software solution that standardizes endoscopic assessment of ulcerative colitis (UC) from colonoscopy videos. Delivers frame-level, quantitative assessments and standardized Mayo Endoscopic Score (MES) outputs with explainable AI for regulatory-ready analysis in clinical trials and research. Available for research and clinical trials.
• DovaVision BE AI-powered real-time Barrett's Esophagus surveillance and early esophageal adenocarcinoma (EAC) detection system. Provides dynamic frame-level detection, granular mapping of dysplastic vs. non-dysplastic tissue, and integrated QA and reporting. In development.
• DovaSound AI-powered intestinal ultrasound (IUS) imaging analysis for rapid, non-invasive IBD monitoring. Uses advanced AI to standardize image capture, interpretation, and reporting for Crohn's disease and ulcerative colitis, reducing operator dependency and variability.

Quantifiable outcome

• 0.867 Quadratic Weighted Kappa (QWK) and 0.869 Intraclass Correlation Coefficient (ICC) for video-level MES scoring
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability8 records

Feature8 records

Partnerships

15 partnerships are on record, tiered core.

• Mayo CliniccoreStrategic or Co-development Partner · 7 October 2025Collaboration on development and validation of DovaVision UC MES for automated scoring of ulcerative colitis. Joint regulatory preparation for FDA clearance. Focus on refining product for seamless integration into gastroenterology workflows.
• AlimentivcoreStrategic or Co-development Partner · 1 May 2025Strategic partnership for commercial deployment of DovaVision UC within Alimentiv's Notō platform for UC clinical trials. Alimentiv, a global GI-focused CRO, provides clinical trial services, medical imaging, and precision medicine. DovaVision is intended for research use in Phase I-IV UC trials.
• University of OxfordcoreStrategic or Co-development PartnerAcademic partnership with Prof. Simon Travis (Professor of Clinical Gastroenterology) and Dr. James East (Professor of Medicine, Endoscopy Research Lead). Dr. Simon Travis is Past President of ECCO.
• University of CalgarycoreStrategic or Co-development PartnerPartnership with IBD Unit led by Dr. Remo Panaccione (Crohn's Colitis Canada Endowed Research Chair in IBD). Dr. Krisztina Gecse collaboration through Amsterdam UMC.
• IBUS (International Bowel Ultrasound)coreStrategic or Co-development PartnerPartnership with IBUS for intestinal ultrasound standards. Dr. Kerri Novak is President-Elect of IBUS and co-founder of IUSCAN.
• University of AugsburgcoreStrategic or Co-development PartnerPartnership with Prof. Helmut Messmann, Past President of ESGE (European Society of Gastrointestinal Endoscopy).
• NYU Grossman School of MedicinecoreStrategic or Co-development PartnerPartnership with Dr. Mike Dolinger, Assistant Professor and co-founder of IUSCAN.
• Indiana University School of MedicinecoreStrategic or Co-development PartnerPartnership with Dr. Doug Rex, Distinguished Professor Emeritus and Past President of ASGE and ACG.
• University of California Irvine Medical CentercoreStrategic or Co-development PartnerPartnership with Dr. Bill Karnes, Clinical Professor of Medicine and Director of High Risk Program.
• CHUM (Centre Hospitalier de l'Université de Montréal)coreStrategic or Co-development PartnerAcademic medical center partnership in Montreal, Canada.
• IUSCAN (Intestinal Ultrasound Group of the United States and Canada)coreStrategic or Co-development PartnerPartnership with IUSCAN for intestinal ultrasound standards and DovaSound development. Co-founded by Dr. Mike Dolinger and Dr. Kerri Novak.
• Western UniversitycoreStrategic or Co-development PartnerPartnership with Dr. Vipul Jairath, Professor of Medicine and McDonald Endowed Chair in IBD Clinical Research, and Chief Medical Officer at Alimentiv.
• IBD Centre of BC / St. Paul's Hospital VancouvercoreStrategic or Co-development PartnerPartnership with Dr. Brian Bressler, Director of IBD training and Lead for IBD Centre of BC.
• University of British ColumbiacoreStrategic or Co-development PartnerAcademic partnership with UBC where Dr. Michael Byrne serves as Clinical Professor of Medicine.
• University of MinnesotacoreStrategic or Co-development PartnerPartnership with Dr. Nasim Parsa, Director of Digital Health and Innovation, Co-director Esophageal Disorders Program.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Iterative Health: Iterative Health applies AI to GI endoscopy with a focus on inflammatory bowel disease, directly competing with DovaVision UC on computer-vision-based disease severity scoring for colonoscopy.
• Virgo Surgical Video Solutions: Virgo offers cloud-based AI video analysis for endoscopy procedures, providing automated capture, editing, and analysis — overlapping with Dova's video-based AI assessment for GI procedures.
• Magentiq Eye: Magentiq Eye develops AI software for colonoscopy quality assessment and polyp detection, directly competing in computer vision-based analysis of endoscopic video.
• Odin Vision: Odin Vision (acquired by Olympus) builds AI tools for endoscopy including polyp detection and lesion characterization, directly overlapping with Dova's GI endoscopy AI focus.
• Wision AI: Wision AI develops computer-aided detection and diagnosis for GI endoscopy, competing with Dova in AI-driven analysis of endoscopic procedures.

Broad incumbents

• Olympus Corporation: Olympus is the dominant endoscopy hardware vendor and has been actively integrating AI (including via its Odin Vision acquisition) into its endoscopy ecosystem, representing both a potential partner and the most significant competitive threat to standalone GI AI software.
• Fujifilm Healthcare: Fujifilm is a major endoscopy system vendor that has been developing AI features (e.g., CAD EYE) for colonoscopy, overlapping with Dova's endoscopy AI functionality from an incumbent's broader portfolio perspective.
• Pentax Medical: Pentax Medical is a global endoscopy equipment manufacturer developing AI integration in its endoscopy systems, positioning it as a broad incumbent adjacent to Dova's endoscopy AI focus.
• Medtronic (GI Solutions): Medtronic operates a GI-focused business (including its acquisition of AI endoscopy assets) that competes in the broader GI care ecosystem, representing an incumbent player with resources to integrate AI endoscopy capabilities.

Emerging players

• EndoBRAIN (Cybernet): EndoBRAIN is an AI-based colonoscopy diagnostic support system developed in Japan for optical biopsy of colorectal polyps, providing a niche but real competitive reference in GI AI imaging.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/Docbot
• LinkedInlinkedin.com/company/docbot-ai
• Facebookfacebook.com/DocbotAI

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds6 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Docbot